45 companies

Harmony Biosciences Holdings

Market Cap: US$2.1b

A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.

HRMY

US$37.27

7D

2.1%

1Y

-0.5%

Global Industrial

Market Cap: US$1.2b

Through its subsidiaries, operates as an industrial distributor of various industrial and maintenance, repair, and operation (MRO) products in the United States and Canada.

GIC

US$32.68

7D

6.9%

1Y

36.6%

Applied Industrial Technologies

Market Cap: US$10.7b

Distributes industrial motion, power, control, and automation technology solutions in the United States, Canada, Mexico, Australia, New Zealand, Singapore, and Costa Rica.

AIT

US$291.74

7D

12.0%

1Y

11.2%

Pegasystems

Market Cap: US$6.5b

Develops, markets, licenses, hosts, and supports enterprise software in the United States, rest of the Americas, the United Kingdom, rest of Europe, the Middle East, Africa, and the Asia-Pacific.

PEGA

US$40.12

7D

-8.2%

1Y

-23.9%

Vita Coco Company

Market Cap: US$3.2b

Develops, markets, and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa, and the Asia Pacific.

COCO

US$58.96

7D

10.5%

1Y

57.1%

Pinterest

Market Cap: US$13.1b

Operates as a visual search and discovery platform in the United States, Canada, Europe, and internationally.

PINS

US$19.60

7D

-11.4%

1Y

-51.0%

ResMed

Market Cap: US$38.9b

Develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.

RMD

US$271.63

7D

5.2%

1Y

14.6%

Stride

Market Cap: US$3.6b

Provides proprietary and third-party online curriculum, software systems, and educational services in the United States and internationally.

LRN

US$87.83

7D

3.8%

1Y

-38.3%

ACADIA Pharmaceuticals

Market Cap: US$4.0b

A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.

ACAD

US$23.56

7D

-6.2%

1Y

27.0%

Page 2 of 2